Literature DB >> 11490197

Inhibitory effect of a TP-receptor antagonist, S-1452, on antigen-induced nasal plasma exudation in guinea pig model for allergic rhinitis.

K Yasui1, F Asanuma, A Arimura.   

Abstract

S-1452, a selective thromboxane (Tx) A(2) receptor (TP-receptor) antagonist, was evaluated in antigen- and U-46619 (a TxA(2) mimetic)-induced guinea pig nasal plasma exudation models. Exposure of the nasal cavity of actively sensitized guinea pigs to aerosolized ovalbumin (OA) caused marked exudation of dye into both the nasal mucosa and nasal airway lumen. These responses were significantly inhibited by S-1452 (30 mg/kg, p.o.) as well as an H(1)-antihistamine, diphenhydramine (5 mg/kg, i.v.). In addition, exposure of the nasal cavity of nonsensitized guinea pigs to aerosolized U-46619 or histamine also resulted in nasal plasma exudation, and S-1452 (1 mg/kg, p.o.) almost completely suppressed the U-46619-induced response but did not affect the histamine-induced one, even at a high dose of 30 mg/kg. These results indicate that TxA(2) as well as histamine may play an important role in antigen-induced nasal plasma exudation in guinea pigs, and S-1452 can be expected to be useful for the treatment of allergic rhinitis. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11490197     DOI: 10.1159/000056114

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  2 in total

1.  The effect of allergic rhinitis with positive skin prick test on choroidal thickness.

Authors:  Alper Yenigun; Ahmet Elbay; Remzi Dogan; Orhan Ozturan; Mehmet Hakan Ozdemir
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-03-06       Impact factor: 2.503

2.  The relationship between Th1/Th2 balance and 1α,25-dihydroxyvitamin D₃ in patients with nasal polyposis.

Authors:  Sule Ozkara; Erol Keles; Nevin Ilhan; Hilal Gungor; Irfan Kaygusuz; Hayrettin Cengiz Alpay
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-02-23       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.